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Incorporating methodological tools that allow uniform and standardized development from the clinical 
pharmacy services to the Pharmaceutical Care practice, is nowadays a necessity. Considering the 
importance of pharmaceutical care provision to elderly patients, this manuscript introduces the design 
and content validation of a standard operating procedure to provide pharmacotherapy follow-up to the 
elderly in nursing homes in Cuba. The procedure was designed based on a deep analysis of documents 
relative to experiences focused on holistic care to elderly patients, criteria for the identification and 
assessment of potentially inappropriate prescriptions and the relationship between functional geriatric 
evaluation and the use of drugs. The content validation was conducted by a panel of experts, using the 
Delphi methodology, through two working sessions. In addition, we used Likert-type scale to evaluate the 
procedure by experts, in line with the indicators described. In general, the criteria issued by the experts 
were very appropriate and allowed us to modify, add or keep several elements of the instrument for 
the final version. The findings demonstrated that the instrument can be used at any level of health care.
Uniterms: Standardized Operating Procedure/validation. Pharmacotherapy Follow-Up/elderly/Cuba. 
Pharmaceutical Care/Cuba. Comprehensive Health Carefor/elderly. Delphi methodology.
INTRODUCTION
Demographic studies have shown an increase in the 
elderly population worldwide (Medeiros et al., 2011). In 
Cuba, people over six decades of life, account for19,4% 
of the population (Oficina Nacional de Estadística e 
Información, 2015; Ministerio de Salud Pública, 2016). 
Life expectancy reaches 78.45 years (Oficina Nacional 
de Estadística e Información, 2013; Ministerio de Salud 
Pública, 2016) and is predicted that by 2050, Cuba will be 
among the largest aging countries in the world (Jiménez, 
2013). Consequently, healthcare strategies should be 
adopted to manage this situation.
The elderly represents the demographic sector 
needing higher health care services and which consumes 
a large amount of drugs, generating significant expenses, 
and sometimes this demographic group makes an 
excessive use of either effective, dubious zero-efficacy 
drugs. Because of this, the elderly group is highly exposed 
to drug-related problems (DRPs), which can interfere with 
the outcome of the therapy (Reyes, Pérez, Martínez, 2006), 
and affect the quality of life of patients, causing the so-
called negative outcomes associated with the medication 
(NOM).
Studies conducted in the United States, Canada 
and several European countries, show that in elderly 
outpatients, Potentially Inappropriate Medication (PIM) 
reaches 10% to 79%, increasing hospitalizations and 
health expenses (Fick et al., 2003; Gongora et al., 2004; 
Fiolová et al., 2005; Barry et al., 2006; Jano, Aparasu, 
2007; Sotoca et al., 2011; García-Gollarte et al., 2012; 
Blanco-Reina et al., 2014; Filomena et al., 2014). For this 
reason, it would of great impact to ensure the effectiveness 
of the drug treatments through the pharmacotherapy 
follow-up for these patients, which must be provided 
on a continuous, systematic and documented basis, in 
collaboration with the patients themselves and the other 
professionals in the system health, in order to achieve 
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tangible results which may improve the quality of life of 
patients (Comité de Consenso, 2007).
Pharmacotherapy follow-up is a practice in which 
the pharmacist assumes the responsibility for the patient’s 
drug-related problems aiming at achieving positive clinical 
outcomes. Several implicit methods have been described, 
for the development of the Pharmacotherapy follow-up 
service: Pharmacotherapy Workup (Cipolle, Strand, 
Morley, 2004); IASER Method (Climente, Jiménez., 
2005); Dáder Method (Silvia- Castro et al., 2003; Faus, 
Amariles, Martínez, 2008); SOAP Approach (Cornelli 
et al., 2005) and the Medication Appropriateness Index 
(Hanlon et al., 1992; Gavilán et al., 2012). 
All of these methods have been designed and 
implemented in different health contexts, being 
incorporated into standard operating procedures. However, 
in their manufacture, consideration was not given to the 
peculiarities of the elderly with respect to the treatment 
of the problems related to the great geriatric syndromes 
(Baster, 2010), the established criteria that define 
inappropriate prescriptions in these patients (Fick et al., 
2012; American Geriatrics Society, 2015; Gallagher et 
al., 2008; Silveira et al., 2015) and the holistic care (bio-
psycho-social perspective),to solve the health problems 
of this population group (Merino, Miguel, Sanz, 2005).
On the one hand, the Medication Appropriateness 
Index was specifically developed to assess the adequacy 
of drug therapy in the elderly. Some authors describe it as 
a method for improving the prescription of specific drugs 
(Stuijt et al., 2008).Otherwise, in Cuban health system, the 
development of Pharmaceutical Care and Pharmacotherapy 
follow-up is limited. There are some professional factors 
that influence in this context: insufficiencies in methods and 
patterns of clinical performance, non-normalization and 
non-generalization of patient-centered activity within the 
health context, low availability of standardized operating 
procedures to provide Pharmaceutical Care services and 
scarce human and material resources. Therefore, the 
exercise is developed as the result of the spontaneity of 
a few professionals (Reyes, 2012; Dupotey, 2013). This 
transcends the fact that Cuban pharmacists have not been 
incorporated as members of the interdisciplinary team of 
geriatric patient care. 
Taking into account the increasing population aging 
in Cuba (Oficina Nacional de Estadística e Información, 
2015; Oficina Nacional de Estadística e Información, 
2013) and the prediction of the percentage of fragile and 
in-need adults in a country (20% of the elderly population) 
(Fariñas, 2013), nursing homes are an important health 
care setting, especially for those patients with a high 
dependence. This group is exposed to the big consumption 
of drugs, associated to their medical, psychological, 
social and functional conditions, increasing the risk of 
medication-related problems, with consequences for the 
patient’s health, the health care institutions and society in 
general. The great use of drugs in the elderly population 
and the morbidity and mortality associated with drugs, 
in the Cuban geriatric population, has been reported 
in several studies (Peña, Redondo, Groning, 2003; 
Reyes, Pérez, Martínez, 2006; Suárez, 2011). Albeit the 
development of research in the area of Pharmaceutical 
Care for the elderly is growing around the world, in Cuba, 
it is still insufficient. 
Moreover, the design and implementation of the 
first Standard Operating Procedure (SOP) to provide 
Pharmacotherapy follow service, in Cuba, was developed 
by Reyes (2012). The instrument was designed and 
validated for inpatients pharmacotherapy follow-up, and 
is applicable to any population. But, its methodological 
structure does not respond to the identification and 
evaluation of main geriatric syndromes, associated with 
the use of drugs.
It has been demonstrated that it is necessary to 
meet the pharmacotherapy needs of the elderly, so as to 
prevent and resolve drug-related problems, by developing 
methodological tools, adapted to the bio-psycho-
social peculiarities and the medication experiences of 
this population, which may allow for the provision of 
pharmacotherapy follow-up service, in a standardized 
and systematic manner, promoting the incorporation of 
pharmacists into interdisciplinary groups for geriatric 
patient care. In this regard, the manuscript presents the 
design evaluation and the content validity of a standard 
operating procedure to provide pharmacotherapy follow-
up to elderly patients institutionalized in nursing homes, 
in Cuba.
MATERIAL AND METHODS
This research study applied the Delphi Method 
(Dalkey, 1967), to design and validate the contents of 
a Standard Operating Procedure in order to provide 
pharmacotherapy follow-up for the elderly, in nursing 
homes, in accordance with the Good Pharmacy Practice 
requirements (OPS, OMS, 1993) and the process approach 
specified in ISO9001: 2008 (ISO Standards, 2009).The 
study was conducted in the period from September 2014 
to August2015. 
The research design involved 5 phases: (1) the 
review of the literature and documentary analysis, (2) 
construction of the initial version of SOP and mailing 
the first-round assessment questionnaire to the expert 
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committee, of the, (3) evaluation of the initial version of 
the SOP by the expert committee, (4) assessment of the 
revised SOP based on findings of round 1 and the expert 
panel feedback and the analysis of the evaluation criteria, 
(5) construction of the final SOP. 
Construction of standard operating procedure 
to provide pharmacotherapy follow-up to the elderly 
in nursing homes 
(1) Review of the literature and documentary analysis
The literature review included all relevant references 
published from 1990 to 2015, describing and analyzing 
the following terms: Pharmaceutical Care Philosophy, 
Pharmaceutical Care Methods and Services (Studies 
conducted by the groups of the University of Florida 
(United States), University of Minnesota (United States), 
University of Granada (Spain), University of Valencia 
(Spain), Pharmacotherapy Follow-Up Procedures and 
Methodologies, Drug-Related Problems, Medication 
and the Elderly, Comprehensive Care for the elderly, 
Potentially Inappropriate Medication used in the Elderly, 
and in the Elderly living in nursing homes. Doctoral 
Thesis of Cuban and foreign authors in the area of 
Pharmaceutical Care were also reviewed.
The search was made using MEDLINE and 
INFOMED databases (the most important websites of 
the Cuban Health System), identifying the appropriate 
references. Each article or bibliographic material was 
systematically reviewed by the researchers using a table 
to outline the following information: objective of the 
study, type of study design, research methodology used, 
and quality assurance indicators of the provided services. 
(2) Construction of the SOP initial version and 
forwarding to the expert committee
After a documentary analysis of literature, three 
steps were taken: (1) a brainstorming session among 
researchers to select the working methods that were 
more in keeping with the research objectives, (2) the 
construction of the SOP initial version and (3) forwarding 
it to the expert committee. 
Ethical considerations
At the beginning, potential participants with 
recognized expertise in pharmaceutical care research, 
pharmacotherapy follow–up; geriatric pharmacology, 
and clinical geriatric medicine, were invited by means 
of an invitation letter (via regular email)to be present 
and they were asked their consent to participate, through 
an informed consent form, to complete our survey. The 
members of the expert committee were selected from 
various geographic areas of Cuba.
The evaluation procedure was carr ied out 
anonymously to avoid the influence of leaders.
Expert Selection 
The expert committee was formed taking into 
account the following inclusion criteria:
1. Bachelors of Science in Pharmaceutical Sciences or 
related professions, whether with a PhD. or MSc. 
and experience in the area of pharmaceutical care, 
pharmacotherapy follow-up or health care provision 
for the elderly.
2. Geriatricians or General Medicine Specialist with a 
degree in geriatrics regardless of the working place.
3. 5 years or more of experience in the health care sec-
tor or in teaching activity.
4. Get a competence coefficient between 0.5 and 1 
(0.5 ≤ k ≤1).
The estimated sample included 13 specialists. The 
response rate for the initial invitation to participate as a 
panelist was 84,6% (11/13).
The competence of the experts was calculated 
using two methods: (1) Self-assessment of the potential 
members, in accordance with the methodology proposed by 
Hurtado (2002) and (2) Analysis of academic and scientific 
performance relative to the subject matter dealt with, 
through the curriculum vitae review, in the last five years. 
The indicators used for the evaluation are shown in Table I.
Experts whose competence coefficient through both 
methods presented the following combinations: High-
High; High-Medium; Medium High; Medium-Medium, 
were finally included.
The Competence Coefficient (K) based on the 
analysis of each expert’s curriculum, was calculated using 
the following equation:
K =Σni = (n1 + n2 + n3 + n4 + n5 + n6)
where: ni: Value corresponding to each indicator i (1 to 6).
The competence coefficient of the expert was rated 
high, medium or low using the following criteria:
25≤ K ≤30 high competence coefficient 
18≤ K ≤24 medium competence coefficient 
12≤ K ≤17 low competence coefficient 
The expert panel was finally composed of nine 
specialists, out of which 77.78% scored a high level of 
competence. All of them completed two rounds of the 
study.
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(3) Evaluation of the first version of the SOP by the 
expert committee. First round
So as to validate the contents of the procedure 
(original version), experts reviewed the printed version 
of the initial draft document, and then completed an 
assessment questionnaire. The review was conducted 
using the Delphi method.
The criteria used for the evaluation of the SOP were 
taken from Moriyama, modified by Reyes in 2013 (Reyes 
et al., 2013) and adapted to the research objectives.
Criteria description:
•  Reasonable and understandable: it makes reference 
to whether the item described from the technical 
point of view conceptually matches the subject mat-
ter and if understanding is adequate 
•  Traceability of the process: the SOP reflects the way 
in which the activity being developed is recorded 
and documented.
•  Adequacy of the indicators: if the presence of each 
one of items included in the instrument, is justified.
•  Sensitive to variations in the phenomenon being 
measured: if the instrument allows to discriminate 
each element of the proposed work systematics (for 
DRP-NOM characterization) and the respective 
indicators that are declared so as to assess the struc-
ture, processes and results of the service.
•  Formal structure: that the SOP fulfills the estab-
lished structure by the World Health Organization.
•  Simplicity of the process: it makes reference to 
the simplicity with which each of the operations 
included in the process.
After reviewing the SOP, experts evaluated each 
indicator using the following Likert-Type Scale: strongly 
agreed (5); in agreement (4); neither in agreement nor 
in disagreement (3); in disagreement (2); and strongly 
disagreed (1). Each panelist had the opportunity to make 
suggestions to improve each indicator of the SOP.
After the analysis of the responses of the first round 
of the study, we examined each recommendation given 
so as to assess the modification or not of the SOP, and 
its subsequent evaluation in the second round. The mean 
rating and the relevant 95% confidence interval (CI) were 
calculated, for each indicator obtained from the first round 
of the assessment. For those indicators which CI > 3, 
the SOP was not modified. When the CI included 3, the 
SOP criteria was considered for a second round. Criteria 
whose CI<3, involved the modification of the SOP. All 
the suggestions given by the experts, were summarized 
an evaluated for a second round, to reach a consensus 
among experts.
(4) Assessment of the reviewed SOP (Second-round)
In the 2nd round, the new version of the printed SOP 
was sent to the experts, with all suggestions in a document 
attached. Experts’ responses were evaluated in accordance 
with Likert-Type Scale of 5 points, following the values: 
5 = in strong agreement; 4 = in agreement; 3 = neither in 
agreement nor in disagreement; 2 = in disagreement and 
1 = in strong disagreement.
The mean rating and the appropriate 95% confidence 
interval (CI) per suggestions, were calculated. Those 
suggestions whose CI>3, led to the SOP modification. 
When the IC≤3,the SOP was not modified.
Statistical analysis of the indicators in each round 
was developed by applying the Delphi Method Software 
(Hurtado, 2002).Each round was conducted in two weeks.
(5) Final design of the SOP
Once the responses and statistical analysis of the 
second round, were analyzed, the final version of the SOP 
was drawn up.









Published papers (national or foreign) ≥2 per year 1 per year None
Participation in the committees for awarding scientific 
degrees ≥2 per 5 years 1 per 5 years None
Presentation of papers at scientific events ≥2 per year 1 per year None
Teaching performance Postgraduate Education
Undergraduate 
Education Does not teach
Awards and honors ≥2 in 5 years 1 in 5 years None
Master degree supervisor and Examining Boards ≥3 in 5 years 1-2 in 5 years None
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FINDINGS
Standard Operating Procedure to provide 
pharmacotherapy follow-up for the elderly (initial 
version)
After reviewing the literature and the documentary 
analysis, the original version of the SOP was designed. 
The design included the following sections: Cover Page, 
Objectives, Applicability, Human resources involved, 
Reference documentation, Responsibilities, Definitions, 
Sequence of activities, Records, monitoring, Quality 
assurance of the Pharmacotherapy Follow-up and 
Annexes. The Objectives, Applicability, Human resources 
involved, Reference documentation and Responsibilities 
differ from the other SOP proposals, specifying that the 
instrument is for the elderly institutionalized in nursing 
homes.
Section Definitions included core concepts related 
to the pharmacotherapy follow-up service. Additionally, 
terms associated with the use of medications in the elderly 
were incorporated: the cascade prescription, elderly 
caregiver, individualized dose, duplicity, chronic illness, 
geriatric interdisciplinary team, geriatric functional 
assessment scale, polypharmacy in the elderly, appropriate 
and inappropriate prescriptions and geriatric syndromes.
Section “Sequence of activities” included core 
elements that characterize the elderly care, such as:
•	 Geriatric interdisciplinary team: Collaborative 
team, in which the main components are physi-
cians, pharmacists and the nursing staff, who work 
together, cooperating for the achievement of the pre-
viously set therapeutic goals, considering the patient 
a member of the team and the center (together with 
his/her family) of the team. Each member should 
be highly familiarized with the tasks and responsi-
bilities of the rest of the members, so that tasks and 
duties are, to some extent, interchangeable (Beers, 
Berkow, 2001). Thus, the inclusion of patients into 
the pharmacotherapy follow-up service can be pro-
moted by any of its members.
•	 Functional geriatric evaluation: Based on the rela-
tionship between geriatric syndromes and drug use 
and the need for a holistic approach to the compre-
hensive care of the elderly, therefore it is considered 
a key element for case documentation.
•	 Identification and classification of DRPs: Criteria 
for the DRPs classification are shown in Table II. 
The list includes various types of DRP: prescription 
errors, dispensing errors, drug storage errors, admin-
istration errors, drug adverse reactions, and others. 
Each drug-related problem identified, will allow to 
determine the therapeutic goal and the appropriate 
pharmacist’s interventions to achieve it. The criteria 
used for identifying prescription errors were based 
on the potentially inappropriate prescriptions for the 
elderly (Fick et al., 2012; Gallagher et al., 2008).
•	 The systematic identification and classification 
of NOM, the care plan implementation and the 
pharmacotherapy follow-up evaluation: The steps 
to identify and classify NOMs and the assessment 
of the interventions outcome, are described, modi-
fying Reyes’ criteria in 2013 (Reyes et al., 2013) 
(Figures 1 and 2). 
•	 Models conduct the initial interview and to draw 
up the pharmacotherapeutic profile for the el-
derly: The models included peculiarities of elderly 
associated to drug use: diseases with great prevalence 
in the elderly, major geriatric syndromes and drugs 
which they usually take. Besides, the pharmacothera-
peutic profile was designed so as to achievea better 
traceability of the evaluation of the DRPs, the NOMs 
and the pharmacists’ interventions, visits and consul-
tations during patient therapy monitoring. In Section 
Quality Assurance of Pharmacotherapy Follow-up a 
system of indicators of structure, process and results, 
was established. They are shown in Table III.
Assessment of the proposal of SOP by the expert 
committee (First Round)
During the assessment of the proposal, all the 
evaluation criteria of the SOP sections showed CI values> 
3, leading to consensus among experts (Table IV). 
However, experts made some suggestions to improve the 
document in some of its parts: Cover Page, Sequence of 
activities, Quality Assurance of Pharmacotherapy Follow-
up and Annexes.
Assessment of the SOP proposal by the expert 
committee (Second Round)
All the suggestions made the experts individually in 
the 1st round, were evaluated by all in the 2nd round. The 
results are shown in Table V. 
Out of the 15 criteria to be assessed in the second 
round, 12 received favorable responses by the experts, 
finding consensus among them. Therefore, the contents 
of the SOP were modified, according to the suggestions 
made in some sections. The three remaining answers 
were unfavorable since there was not consensus among 
the experts.
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TABLE II - Criteria for the classification of DRPs
DRPs Types Description 
Prescribing errors
•	 The patient uses a drug that is unnecessary. 
•	 Drugs indicated, but not prescribed (when there is no contraindication to its use). 
•	 Potentially inappropriate medication use in older adults: regardless of diagnoses or conditions.
•	 Potentially inappropriate medication use in older adults: considering diagnoses or conditions 
•	 Interactions: Drug-drug; Drug-disease; Drug-food; Drug-testing laboratory.
•	 The dose, dosing interval or duration of treatment prescribed by the doctor is inadequate.
•	 The indication is inadequate. 
•	 Individualization of treatment according to age, sex, weight (obesity or malnutrition value), 
renal function, liver function, genetic polymorphism (assess whether patients can be slow or fast 
metabolizers or can be fast or slow acetylators); allergies (eg. antibiotics, NSAIDs); Other health 
problems that interfere with treatment and have not been taken into account between potentially 
inappropriate medications.
•	 Incomplete prescription: default: the dosage form, strength or quantity. 
•	 Bad prescribed master formula.
•	 Incomprehensible prescription
•	 Contraindications: contraindicated drug according to patient characteristics, taking into account the 
geriatric syndromes.
•	 Treatment not cost / effective.
•	 Duplicate therapy: Prescription of two drugs from the same chemical structure or pharmacological 
group with negative effects (non-benefit or harmful) for patient clinical condition.
•	 Cascade prescription: drug prescription to treat adverse reactions caused by another drug.
Dispensing errors
•	 Change dosage form or dosage strength.
•	 Wrong medicine.
•	 Insufficient information provided by the pharmacist about drug use
•	 Others
Drug Storage errors •	 Non-compliance of storage or conservation standards: hygroscopicity, photosensitivity, inadequate storage temperature, and others.
Administration errors
•	 Drug-drug interaction by co-administration
•	 Drug-food interaction (without prescriber’s responsibility) 
•	 Non-compliance of the administration schedule or dose range prescribed
•	 Inadequate dosage form for the case. 
•	 Non-compliance of the prescribed dose (missing or wrong)
•	 Speed inappropriate administration (parenteral drug use).
•	 Inadequate preparation conditions.
•	 Wrong patient administration
•	 Dilution or reconstitution inadequate
•	 Change of the administration route 
•	 Self-medication
•	 Medication non-adherence
Adverse drug reaction •	 Causative relationship between a health issue (undesirable effect) and the administration of one or more drug.
Others •	 Non-availability of drugs in pharmacy service. 
•	 Any other drug-related problem that can cause NOM and has not been described previously.
Legend: DRPs: Drugs–Related Problems. NOM: Negative Outcomes associated with Medication. SAIDs: Nonsteroidal anti-
inflammatory drugs.
•	 Sections Cover Page, Object, Applicability and 
Human Resources involved were modified, because 
most of the experts considered that the SOP use is 
not restricted to nursing homes, and it can be applied 
at any level of health care. So, the proposal title was 
“Standard Operating Procedure to provide Pharma-
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cotherapy Follow-up for the Elderly (PNT-SFTAM/ 
Acronym in Spanish language).
•	 Number “01” was included in the SOP code, be-
ing represented by the same acronym: as PNT-
SFTAM-01.
•	 The meaning of the auto shapes used in the System-
atics for the detection and classification of NOMs 
(Figure 1) and in the Systematics for the evaluation 
of the pharmacist’s interventions in the pharmaco-
therapy follow-up (Figure 2), were specified.
•	 Three phases were explained in the Section Sequence 
of activities (Figure 3), which were described as fol-
lows:
o Initial assessment of the patient: To deter-
mine the patient’s drug-related needs in the or-
der of the indication, effectiveness and safety, 
service offering to the patient, creating of the 
pharmacoterapeutic profile, documenting the 
FIGURE 1 - Systematic detection and classification of NOM.  
Legend: NOM: Negative Outcomes associated with Medication.
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case and identifying drug therapy problems 
(DRPs) and negative outcomes associated 
with medication (NOMs). 
o Design and implementation of a therapeutic 
patient care plan: Establish goals of therapy, 
select appropriate interventions for: resolution 
of drug therapy problems, prevention of drug 
therapy problems and the evaluation of the 
results of interventions.
o Monitoring and evaluation of pharmaco-
therapy follow-up results in the patient: 
Include analysis of the final follow-up assess-
ment (Assessment of the scope of therapeutic 
goals for the patient’s care plan and the solu-
tion or prevention of NOM) Satisfaction of the 
patient / caregiver is evaluated.
•	 The proposed changes relating to the incorporation 
of other types of DRPs (insufficient information 
provided by pharmacist about drug use, medication 
non-adherence and non-availability of drugs), were 
accepted as shown in Table I. Likely, the other sug-
gestions issued by the experts were modified in the 
SOP.
Construction of final SOP
The diagram of the final SOP version is shown in 
Figure 4, according to the results of both rounds.
FIGURE 2 - Systematic evaluation of the pharmacist’s interventions in the pharmacotherapy follow-up. 
Legend: DRP: Drugs-Related Problem. NOM: Negative Outcomes associated with Medication.
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DISCUSSION 
Proposed Standard Operating Procedure to 
provide pharmacotherapy follow-up to the 
elderly
The conceptual framework of the first SOP version 
corresponds to the theoretical and methodological 
elements of an organizational system designed to provide 
Pharmacotherapy follow-upservice for the elderly in 
nursing homes. It takes into account some relevant 
references in this area, conducted by Gutiérrez (2006), 
Reyes et al. (2013), Reyes (2012) and Dupotey (2013). 
Gutiérrez, made an important contribution to the Health 
System of Spain, who developed Quality Operating 
Procedures for the healthcare activities in community 
pharmacies.
In Cuba, it is worth highlighting the research 
conducted by Reyes (2012), Reyes et al. (2013) and 
Reyes et al. (2014) who developed a systemic approach 
to implementing pharmaceutical care services in hospitals. 
A SOP to provide pharmacotherapy follow-up at this 
level of health care, was validated. These works present 
a system of the vital relationships between patient-drug, 
TABLE III - Quality assurance indicators for Pharmacotherapy Follow-up service
Component Indicators /description
Structure
Availability of professionals (I1): To estimate the real availability of pharmacists providing 
pharmacotherapy follow-up. 
Training of professionals (I2): To estimate percentage of pharmacists with training program in 
pharmacotherapy follow-up activity.
Time dedicated on pharmacotherapy follow-up (I3): To estimate the average time required by a 
pharmacist in pharmacotherapy follow-up. The interview time, study time and intervention time were 
included.
Availability of literature (I4): To assess the available literature versus the suggested literature to provide 
the service.
Process
DRPs per patient in pharmacotherapy follow-up (I5): To estimate the number of DRPs per patient in 
pharmacotherapy follow-up.
DRPs per validated medication order (I6): To estimate the number of DRPs per validated medication 
order. 
Prescribing errors per validated medication order (I7): To estimate the number of Prescribing DRPs 
per validated medication order. 
Dispensing errors per validated medication order (I8): To estimate the number of Dispensing DRPs 
per validated medication order. 
Administration errors per validated medication order (I9): To estimate the number of Administration 
DRPs, per validated medication order. 
Drug Storage errors per validated medication order (I10): To estimate the number of Storage DRPs, 
per validated medication order. 
Adverse Drug Reactions detected per validated medication order (I11): To estimate the number of 
ADR-DRP detected, per validated medication order.
Pharmacist’s interventions acceptance rate (I12):To estimate the rate of acceptance of the pharmacist’s 
interventions.
Outcomes
Impact of pharmacist’s interventions associated to NOMs (I13): To estimate the impact of the 
pharmaceutical interventions in the resolution of NOMs.
Appropriateness of pharmacist`s interventions for suspected NOMs (I14): Estimate the impact of the 
pharmaceutical interventions in preventing NOMs.
Patient`s satisfaction(I15): Estimate the degree of satisfaction of patients and/or family.
Healthcare provider’s satisfaction (I16): Estimate the degree of satisfaction of the healthcare providers 
in the interdisciplinary team.
Legend: ADR: Adverse Drugs Reactions; DRPs: Drugs–Related Problems; NOM: Negative Outcomes Associated with Medication.
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the pharmacist and the others health team members. The 
structure, the process and the outcomes are identified as 
quality components of the system, connected with all 
clinical services developed by the pharmacist.
Another theoretical reference for this research 
was developed by Dupotey (2013), who presents a new 
paradigm for the improvement of pharmaceutical care 
in Cuba, based on a comprehensive vision and holistic 
approach to provide Pharmaceutical Care by pharmacists, 
with the integrated participation of the Cuban Health 
System managers, health providers, academics, and 
patients. This paper highlights the evaluation of the bio-
psycho-social condition of the patient, to understand its 
drug-related problems. This is an essential aspect to be 
considered in the healthcare service provided for the 
elderly, because drug therapy in geriatrics requires a 
more humanistic approach than just a clinical perspective, 
centered in the elderly patient as an individual. (Merino, 
Miguel, Sanz, 2005).
The SOP proposal defends geriatric patient care, 
not only from the harmonic analysis of their clinical 
condition and use of drugs based on the inadequacy of 
medication criteria (Fick et al., 2012; American Geriatrics 
Society, 2015; Gallagher et al., 2008; Silveira et al., 2015; 
Holt, Schmiedl, Thurmann, 2010), and its relationship 
with geriatric syndromes. The SOP reveals the need 
of incorporating the bio-psychosocial condition of the 
patient, to obtain the necessary holistic assessment for 
the elderly, in a greater contribution and relevance of the 
pharmacist to solve the health problems of this particular 
population group, which is growing at an accelerated pace. 
(Oficina Nacional de Estadística e Información, 2013).
Likewise, a quality assurance system in the 
SOP, incorporates the structure, process and outcomes 
indicators, which allow the evaluation of pharmacotherapy 
follow-up service for the elderly. This contributes to 
the continuous improvement of the provided service, 
responding to the World Health Organization (WHO)’s 
statements that mentions: … health systems should 
support and enhance the implementation and practice 
of pharmaceutical care by measuring, evaluating and 
improving pharmacy practice activities, using the 
TABLE IV - Assessment results by the expert committee (First Round)
Criteria Mean [IC] Suggestions by the experts
Reasonable 4.44  [4.91, 3.97]
•	 To define stages or phases in the Pharmacotherapy follow-up process.
•	 To clarify the usefulness of the functional geriatric assessment scale. 
Traceability 4,55  [5.00, 4.08]
•	 To include the brachial data and abdominal circumference of patient.
•	 To include the homeopathic treatment in the pharmacological anamnesis.
•	 To include as pharmacist’s intervention the suggestion for determining and 
monitoring biochemical tests.
Adequacy 4.66  [4.98, 4.34]
•	 To include in dispensing errors "insufficient information provided by the pharmacist 
about the use of the drug".
•	 To include in administration errors “Medication non-adherence”.
•	 To include in other DRPs “non-availability of drugs in pharmacy service”. 
•	 To specify the standard number of pharmacists who provide pharmacotherapy 
follow-up service.
•	 To describe the standard average time of pharmacotherapy follow-up service.
•	 To define the standard recommended literature.
Sensitivity 4,66 [4.98, 4.34] •	 To record all types of ADR, not only moderate and severe.
Structure 4,77 [5.00, 4.49]
•	 To specify in the SOP title, that the instrument will be developed for elderly patients 
in nursing homes.
•	 To assign to the SOP, an identification code, for further modifications.
•	 To clarify the meaning of the auto shapes used in the diagrams.
Simplicity 4,33  [4.78, 3.88] -
Legend: ADR: Adverse Drugs Reactions. DRPs: Drugs - Related Problems.CI: confidence interval.
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conceptual framework of continuous quality improvement. 
(Widenmayer, Summers, Mackie, 2006).
The designed indicators in the SOP, responding to 
the Donadebian quality approach (Donadebian, 1988). 
These indicators consider the three phases of the Sequence 
of activities: Initial assessment of the patient; Design and 
implementation of a therapeutic patient care plan and 
evaluation of results in the patient.
Regarding the structure indicators, there are no 
differences when comparing it with the one proposed 
by Reyes et al. (2013). However, the process indicators 
incorporate others which are not addressed by this author, 
which are identified as I5, I7, I8, I9, I10 and I11. These are 
oriented to determine the DRPs per validated medication 
order, specifically those related to the prescription, 
dispensing, administration, storage and ADR and thus, to 
design activities in order to improve the staff training and 
process control. The NOM is the clinical consequence of 
the DRP, and the pharmacist’s responsibility is to prevent 
and to resolve them. One NOM may be associated with 
multiple DRPs. From this point of view, the evaluation of 
NOM was excluded of the process indicators proposed by 
Reyes and incorporated as outcome indicators. 
The impacts of the pharmacist´s interventions 
to resolve NOM (I13) and to prevent NOM (I14) were 
included. Both indicators express the pharmacist’s role 
in the improvement of the pharmacotherapy and if this 
professional is able to gain benefits with the patient’s 
care plan implemented. There are so many examples 
of these indicators, whose usefulness in evaluating the 
TABLE V - Assessment results by experts in the second round
Criteria Mean [IC] Result
1. To specify in the SOP title, that the instrument will be developed for elderly patients 
in nursing homes.
3,25 
[4.40, 2.10] Not modified
2. To assign to the SOP, an identification code for further modifications.(01)
4,33 
[4.89, 3.77] Modified
3. To clarify the meaning of the autoshapes used in the diagrams.
4,44 
[5.00,3.58] Modified
4. To describe stages or phases in the Pharmacotherapy follow-up process, in the 
“Sequence of activities” section.
4,11  
[4.71, 3.51] Modified




6. To include in dispensing errors “insufficient information provided by pharmacist 
about the use of the drug”.
4,33  
[5.00, 3.61] Modified
7. To include in administration errors “Medication non adherence”.
4,55  
[5.00, 3.89] Modified
8. To include in other DRPs “non-availability of drugs in the pharmacy service”.
4,22  
[4.93, 3.51] Modified
9. To record all types of ADR, not just moderate and severe.
4,66 
[4.98, 4.34] Modified
10. In the structure indicator “Availability of the professionals (I1)” to define the 
standard number of pharmacists who provide pharmacotherapy follow-up service.
4,66  
[4.98, 4.34] Modified
11. In the structure indicator “Pharmacotherapy follow-up Time (I3)” to define the 
standard average time of the Pharmacotherapy follow-up service.
3.77  
[4.56, 2.99] Not modified 
12. In the Structure indicator “Availability of the literature (I4)”, to define the standard 
recommended literature.
3,88  
[4.98, 2.78] Not modified
13. In the section “Initial Interview Form” to include the brachial data and abdominal 
circumference of patient, to determine the body mass index in the bedridden elderly.
4,77 
[5.00, 4.49] Modified
14. In Annex, to include the homeopathic treatment in the pharmacological anamnesis.
4,33 
[4.78, 3.88] Modified
15. In Annex, to include as a pharmacist’s intervention, the suggestion for determining 
and monitoring biochemical tests.
4,66 
[4.98, 4.34] Modified
Legend: ADR: Adverse Drugs Reactions. DRPs: Drugs – Related Problems.CI: Confidence Interval.
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impact and adequacy of the pharmacists’ interventions, 
pharmacotherapy results and/or clinical, pharmaco 
economic, humanistic outcomes, have been reported by 
several authors, with remarkable results in the patient´s 
quality of life. (Climente, Jiménez, 2005).
Assessment of the SOP proposal by the experts 
committee (First Round) 
The confidence interval values obtainedin the 
criteria assessment for the SOP proposal revealed a high 
FIGURE 3 - Sequence of activities for the pharmacotherapy follow-up. 
Legend: DRPs: Drugs-Related Problems. NOM: Negative Outcomes associates with Medication.
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FIGURE 4 - Diagram of the Standard Operating Procedure for pharmacotherapy follow-up in the elderly. 
Legend: DRPs: Drugs-Related Problems. NOM: Negative Outcomes associates with Medication.
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degree of agreement among experts, which demonstrates 
the validity of the contents of the proposed instrument to 
provide pharmacotherapy follow-up for the elderly.
SOP assessment reviewed by the expert 
committee (Second Round)
The mean and CI values of the suggestions under 
evaluation by the experts, likely showed a high degree of 
agreement among experts. It was possible to re-design the 
SOP initial version and to achieve a content validity of the 
final reviewed instrument, to provide pharmacotherapy 
follow-up for the elderly. 
Through the SOP analyses, no restrictions to 
nursing homes were introduced and the possibility of 
applicability at any level of health care for the elderly was 
recommended. The inclusion of code (01) for identifying 
the document, which will make possible the differentiation 
from other versions, which may appear with respect to the 
values of the of quality assurance indicators.
To respond the experts’ criterion regarding the 
definition of stages in section “Sequence of activities”, 
Cipolle, Strand and Morley (2004) and Dupotey (2013) 
criteria, were used.
Limitations to this study
Despite ensuring the anonymity of the experts who 
made up the panel, so as to avoid the effect of leaders, there 
may be the case that experts exchanged their views with 
each other, which can lead to information bias.
CONCLUSIONS
The Standard Operating Procedures to provide 
pharmacotherapy follow-up for the elderly was designed 
from a detailed documentary analysis that took into 
account: the need for holistic care to elderly patients, the 
criteria of inappropriate medication for this population and 
the relationship between functional geriatric evaluation 
and the use of drugs.
Two working sessions were established to achieve 
the procedure content validation, which was reviewed by 
an expert committee using the Delphi methodology. High 
degree of agreement among evaluators, was achieved, 
which allowed to improve the initial version of the 
instrument and to construct the final procedure.
The validated SOP is a tool that can be used by 
pharmacists for Pharmacotherapy follow-up forthe elderly 
at any level of healthcare. 
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